These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 32618501

  • 1. Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer.
    Ss Pindiprolu SK, Krishnamurthy PT, Ghanta VR, Chintamaneni PK.
    Nanomedicine (Lond); 2020 Jul; 15(16):1551-1565. PubMed ID: 32618501
    [Abstract] [Full Text] [Related]

  • 2. Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells.
    Pindiprolu SKSS, Chintamaneni PK, Krishnamurthy PT, Ratna Sree Ganapathineedi K.
    Drug Dev Ind Pharm; 2019 Feb; 45(2):304-313. PubMed ID: 30348020
    [Abstract] [Full Text] [Related]

  • 3. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M.
    Mol Pharm; 2015 Apr 06; 12(4):1105-20. PubMed ID: 25661724
    [Abstract] [Full Text] [Related]

  • 4. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
    Pindiprolu SKSS, Krishnamurthy PT, Dev C, Chintamaneni PK.
    Chem Phys Lipids; 2021 Mar 06; 235():105033. PubMed ID: 33385372
    [Abstract] [Full Text] [Related]

  • 5. Phenylboronic acid modified lipid nanocarriers mediated co-delivery of immunocytokine TRAIL and gamma-secretase inhibitor to triple negative breast cancer cells and cancer stem cells.
    Pindiprolu SKSS, Avasarala H, Dinakaran SK.
    Med Hypotheses; 2021 Dec 06; 157():110716. PubMed ID: 34731681
    [Abstract] [Full Text] [Related]

  • 6. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J, Chen X, Ward T, Pegram M, Shen K.
    Tumour Biol; 2016 Jul 06; 37(7):9825-35. PubMed ID: 26810188
    [Abstract] [Full Text] [Related]

  • 7. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L, Gao Y, Zhang X, Wang J, Ding D, Zhang Y, Zhang J, Chen H.
    Oncotarget; 2016 Jul 05; 7(27):42126-42138. PubMed ID: 27363012
    [Abstract] [Full Text] [Related]

  • 8. Effective inhibition of breast cancer stem cell properties by quercetin-loaded solid lipid nanoparticles via reduction of Smad2/Smad3 phosphorylation and β-catenin signaling pathway in triple-negative breast cancer.
    Hatami M, Kouchak M, Kheirollah A, Khorsandi L, Rashidi M.
    Biochem Biophys Res Commun; 2023 Jul 05; 664():69-76. PubMed ID: 37141640
    [Abstract] [Full Text] [Related]

  • 9. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim H, Yin T, Fan S, Shen Q.
    Oncogene; 2018 Sep 05; 37(39):5292-5304. PubMed ID: 29855616
    [Abstract] [Full Text] [Related]

  • 10. Quercetin-loaded solid lipid nanoparticles exhibit antitumor activity and suppress the proliferation of triple-negative MDA-MB 231 breast cancer cells: implications for invasive breast cancer treatment.
    Hatami M, Kouchak M, Kheirollah A, Khorsandi L, Rashidi M.
    Mol Biol Rep; 2023 Nov 05; 50(11):9417-9430. PubMed ID: 37831347
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L, Nuncia-Cantarero M, Morcillo-Garcia S, Nieto-Jimenez C, Burgos M, Corrales-Sanchez V, Perez-Peña J, Győrffy B, Ocaña A, Galán-Moya EM.
    Cell Oncol (Dordr); 2020 Jun 05; 43(3):431-444. PubMed ID: 32166583
    [Abstract] [Full Text] [Related]

  • 14. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
    Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D.
    Mol Ther; 2019 Jul 03; 27(7):1252-1261. PubMed ID: 31085078
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension.
    Braga CL, Felix NS, Teixeira DE, Vieira JB, Silva-Aguiar RP, Bose RM, Antunes MA, Rocha NN, Caruso-Neves C, Cruz FF, Rocco PRM, Silva PL.
    Eur J Pharmacol; 2020 Nov 15; 887():173438. PubMed ID: 32795515
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A, Upadhyay P, Ghosh A, Bose A, Gupta P, Chattopadhyay S, Chattopadhyay D, Adhikary A.
    Biochim Biophys Acta Gen Subj; 2021 Mar 15; 1865(3):129841. PubMed ID: 33412224
    [Abstract] [Full Text] [Related]

  • 19. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S.
    Breast Cancer Res Treat; 2015 Jun 15; 151(2):281-94. PubMed ID: 25904215
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.